diabetes patients

insulin therapy

type diabetic

glycaemic control

glucose control

glucagon-like peptide

blood glucose

Computers in Biology and Medicine

Metformin is the preferred first-line medication for management of type 2 diabetes and prediabetes. However, over a third of patients experience primary or secondary therapeutic failure. We developed machine learning models to predict which patients initially prescribed metformin will achieve and maintain control of their blood glucose after one year of therapy. We performed a retrospective analysis of administrative claims data for 12,147 commercially-insured adults and Medicare Advantage beneficiaries with prediabetes or diabetes. Several machine learning models were trained using variables available at the time of metformin initiation to predict achievement and maintenance of hemoglobin A1c (HbA1c) < 7.0% after one year of therapy. AUC performances based on five-fold cross-validation ranged from 0.58 to 0.75. The most influential variables driving the predictions were baseline HbA1c, starting metformin dosage, and presence of diabetes with complications. Machine learning models can effectively predict primary or secondary metformin treatment failure within one year. This information can help identify effective individualized treatment strategies. Most of the implemented models outperformed traditional logistic regression, highlighting the potential for applying machine learning to problems in medicine.

Stacked classifiers for individualized prediction of glycemic control following initiation of metformin therapy in type 2 diabetes